To ask the Secretary of State for Health and Social Care, what guidance has been published for clinicians regarding covid-19 anti-viral treatment for clinically extremely vulnerable people.

From the 16 December 2021, the highest risk patients in the United Kingdom can access molnupiravir, an antiviral treatment, as well as monoclonal antibody treatments from COVID Medicines Delivery Units. Patients are assessed by clinicians and offered antiviral or antibody treatments if eligible. Clinical guidance was published on 16 and 24 December 2021 for patients at the highest risk of progression to severe COVID-19 including hospitalisation and death to access to these new treatments. The clinical access policy is available at the following links:

https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103184

https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103186

In addition, oral antiviral treatments are available through the PANORAMIC national study, run by the University of Oxford. This study is open to clinically eligible individuals in the UK. Information on eligibility for the study is available at the following link:

https://www.panoramictrial.org/